Sanara MedTech Inc.
About Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $103.1M
- Net income
- -$37.6M
- Total assets
- $72.9M
- Market cap
- $205.6M
- Gross margin
- 92.7%
- Operating margin
- 7.1%
- Net margin
- -36.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $103.1M
- Cost of revenue
- $7.5M
- Gross profit
- $95.6M
- Operating expenses
- $88.3M
- Operating income
- $7.3M
- Net income
- -$37.6M
- EPS (basic)
- $-4.36
- EPS (diluted)
- $-4.36
Balance sheet
- Total assets
- $72.9M
- Current assets
- $33.5M
- Total liabilities
- $67.0M
- Current liabilities
- $18.6M
- Shareholders’ equity
- $5.9M
Cash flow
- Operating cash flow
- $6.8M
- Investing cash flow
- -$15.0M
- Financing cash flow
- $8.9M
- Net cash flow
- $700.6K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $205.6M
- EPS (diluted)
- $-4.36
- Shares outstanding
- 8.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 2, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $37.6M in FY2025.
- Revenue grew 327% from FY2021 to FY2025.
- Gross margin of 92.7%, net margin -36.4%.
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sanara MedTech Inc..
Write a review
News about Sanara MedTech Inc.
News & sentiment via Polygon.io
